7681
document
Fibrin application for preventing lymphocysts after retroperitoneal lymphadenectomy in patients with gynecologic malignancies . OBJECTIVE We performed a randomized , prospective trial to assess the impact of fibrin glue on the incidence of lymphocysts after systematic pelvic or pelvic and paraaortic lymphadenectomy in patients with gynecologic malignancies . METHODS Ninety-three consecutive patients with gynecologic pelvic malignancies who underwent surgery including pelvic or pelvic and paraaortic lymphadenectomy were randomized during surgery to be treated with fibrin glue or not . Serial computed tomography ( CT ) scans were performed during follow-up . CT findings of a smooth and thin-walled cavity filled with a water-equivalent fluid , sharply demarcated from its surroundings and without signs of infiltration were interpreted as lymphocysts . RESULTS Forty-seven patients ( 51 % ) were treated with fibrin glue and 46 ( 49 % ) were not . All 93 patients underwent pelvic lymphadenectomy ; 15 patients ( 32 % ) of the fibrin group and 12 ( 26 % ) of the controls also underwent paraaortic lymphadenectomy . We found no significant differences between patients who received fibrin glue and those who did not . CONCLUSION Intraoperative application of fibrin glue did not reduce the rate of postoperative lymphocysts after lymphadenectomy and had no impact on any follow-up parameter . Its use seems not to be indicated in systematic gynecologic pelvic or pelvic and paraaortic lymphadenectomy .
7682
Intervention_Pharmacological
Fibrin application
7683
Intervention_Pharmacological
fibrin glue
7684
Intervention_Pharmacological
treated with fibrin glue
7685
Intervention_Control
not
7686
Intervention_Physical
Serial computed tomography ( CT ) scans
7687
Intervention_Pharmacological
fibrin glue
7688
Outcome_Physical
lymphocysts
7689
Outcome_Other
no significant differences
7690
Outcome_Physical
reduce the rate of postoperative lymphocysts
7691
Outcome_Other
no impact
7692
Outcome_Other
follow-up parameter
7693
Participant_Condition
gynecologic malignancies
7694
Participant_Condition
gynecologic malignancies
7695
Participant_Sample-size
Ninety-three
7696
Participant_Condition
gynecologic pelvic malignancies
7697
Participant_Sample-size
93